Forward looking statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. The Company’s financial measures under GAAP include substantial one-time charges related to its acquisitions and ongoing amortization expense related to acquired intangible assets that will be recognized over the useful lives of the assets and charges related to executive severance. Management believes that presentation of operating results that excludes these items provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP to non-GAAP financial guidance is provided under the investor section of Myriad’s corporate website.
Our purpose-driven mission to transform and improve lives is more relevant than ever.

We have a strong, compelling market opportunity as a leader in genetic testing and precision medicine.

But the market had been changing faster than we were.

We must transform to win, put patients and customers first, reset our base, simplify our business, and drive new commercial capabilities.

The new Myriad Genetics will create new growth opportunities for us all.

Paul J. Diaz
President and CEO
A Powerful Thesis for Transformation

- Large, growing market opportunity - $10B+
- Economics of molecular diagnostics support sustainable, profitable growth
- Respected portfolio, scientific know-how and reach
- Opportunities to elevate our products to full potential and advance new innovations
- Need to reset our competitive and financial position by reducing complexity and cost
- Winning culture and strong leadership team will be the foundation for delivering on our mission, market leadership, long-term growth and profitability
Four-point strategic roadmap

1. Put patients and customers first
   - Convey our unique value proposition
   - Play offense with price positioning and reimbursement
   - Ramp up consumer and digital marketing
   - Enable frontline and virtual sales with best-in-class training and support

2. Build new tech-enabled commercial capabilities
   - Increase awareness and access
   - Bolster differentiation with messaging and innovation
   - Reinforce clinical utility
   - Maximize cross-sell and synergies across the portfolio

3. Elevate core products to full potential
   - Explore opportunities to invest in new products, innovations and technologies
   - Direct-to-consumer marketing models
   - Partnerships with payers, health systems, and other providers
   - Dataset monetization

4. Create new avenues of growth
Transformation phases and objectives

PHASE I: RESET THE BASE
- Continue COVID volume recovery and execute on near-term opportunities
- Prioritize product innovation, research and technology initiatives
- Establish firm financial position, reduce complexity and cost
- Develop winning, customer-centric, technology-enabled commercial model
- Develop and launch comprehensive transformation plan

PHASE II: ELEVATE CURRENT PORTFOLIO TO FULL POTENTIAL
- Execute on strategic priorities and launch new technology-enabled commercial model
- Improve financial performance and transparency with investors
- Enhance reimbursement and revenue cycle capabilities

PHASE III: ACCELERATE GROWTH
- Invest in innovation, research and partnerships to accelerate organic growth
- Build commercial capabilities to support new products and potential M&A
A cohesive enterprise-wide commercial strategy framework

Our business has to **consistently reinvent itself and adapt to evolving product lifecycles** to stay competitive and deliver **long-term profitable growth**

Deliver a crisp value proposition, aligned with customer needs
Reduce friction with customers through tech innovation
Optimize pricing and bring cost down to maximize operating income
Build a more effective and cost-efficient sales model
Develop capabilities to move towards direct-to-consumer
Build pipeline of new products to refuel growth
Three Focused Business Units

**Women’s Health**
- Serving women assessing risk of cancer and offering pre-natal tests for women

**Oncology**
- Genetic testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs.

**Mental Health**
- Helping physicians understand how genetic alterations impact patient response to antidepressant and other drugs.

**Mission**

**Market**

**Products**

**Potential Catalysts**
- Improving prenatal economics
- Digital marketing and customer experience

<table>
<thead>
<tr>
<th>Market</th>
<th>Growing</th>
</tr>
</thead>
<tbody>
<tr>
<td>$4B U.S Market</td>
<td>10%</td>
</tr>
<tr>
<td>$4B U.S Market</td>
<td>8%</td>
</tr>
<tr>
<td>$5B U.S Market</td>
<td>15%</td>
</tr>
</tbody>
</table>

**Women’s Health Products**
- Foresight
- riskScore
- Prequel

**Oncology Products**
- myRisk
- Prolaris
- myChoice
- EndoPredict
- BRACAnalysisCDx
- genesight

**Mental Health Products**

**Potential Catalysts**
- Somatic strategy – tumor testing
- Prolaris reimbursement
- International CDx opportunity
- Primary care expansion
- Pricing/reimbursement strategy
- Telehealth partnerships

©2019 Myriad Genetics, Inc. All rights reserved.
Women’s Health Key Opportunities

**Improving Prenatal Outlook**
- **Prequel®** Amplify™ for prenatal testing
- Revenue cycle management, easier patient payment models
- Evidence Street recommendation for Foresight®
- ACOG recommendations for average risk prenatal testing

**Increasing Access, Reducing Disparities**
- Expanding carrier screening to broaden access to testing
- Reducing healthcare disparities across racial, economic and social lines
- riskScore® global ancestry launch

**Customer Experience, Digital Marketing**
- Accelerating the patient journey – interest to testing
- myRisk® portal
- Patient cost estimator
- AI counseling tools
Oncology Key Opportunities

**myChoice CDx Kit Expanding Global Access**
- Exclusive *myChoice® CDx* kit partnership with Illumina for select international markets

**Prolaris Reimbursement Prostate Cancer Testing**
- Coverage for non-favorable intermediate and high-risk patients by Medicare

**Companion Diagnostics International Expansion**
- *myChoice® CDx* launch in Japan and Europe
- Pancreatic and prostate cancer approvals in Japan for *BRACAnalysis® CDx*
International Growth with Companion Diagnostics

• European lab tech-transfer deals in France/Germany for myChoice® CDx
• Illumina myChoice® CDx kit collaboration

• Japan now largest market outside U.S. with $7.5M in revenue in Sep. (up 200% YoY)
• Pancreatic and prostate approvals double CDx target population in Japan
• Japanese approval of myChoice® CDx
### Mental Health Key Opportunities

<table>
<thead>
<tr>
<th>Pricing and Reimbursement</th>
<th>Telehealth Partnerships</th>
<th>Primary Care Expansion</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Re-evaluating pricing and reimbursement strategy</td>
<td>• Expanding telehealth partnerships</td>
<td>• Sales rep additions</td>
</tr>
<tr>
<td>• Value demonstration projects with payers</td>
<td>• First signed in Sept. ‘20</td>
<td>• Direct-to-consumer marketing initiatives</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Increased focus on inside sales</td>
</tr>
</tbody>
</table>
GeneSight Primary Care Launch

TARGET CLINICIANS | Top antidepressant prescribers - high United Healthcare/Medicare potential

- **Expanded field force focus on primary care**
  - Net increase of 35 reps
  - 13% sequential test growth in Dec. quarter and >2,000 new ordering doctors

- **Online engagement – 135,000 monthly site visitors**
  - 5% complete patient information form
  - 25,000 monthly find-a-provider searches

- **Targeted direct-to-consumer advertising**
  - Television, Print, Radio, Digital and Social in key markets

- **Increased inside sales capabilities**
  - Outbound telemarketing and follow-up
Seamless Tech-Enabled Customer Experience

- Education
- Telehealth
- Access
- Portals
Technology Enabled Customer Initiatives

**Education**
- MyGeneHistory - Risk assessment at home or in clinic, EMR integration, AI-driven guides, Personalized workflow

**Telehealth**
- Tele-Psychiatry partnerships to facilitate test orders

**Access**
- Transparent, personalized out of pocket cost estimates

**Portals**
- Patient and provider portals for results delivery and order management.
- 30% reduction in time per order
- EMR scale-out to 275+ new interfaces
Driving digital engagement and conversion

Hereditary Cancer Quiz
Driving follow through

- Patient Interest: 993,497
- Quiz Completions: 517,489
- Criteria Qualifications: 289,839
- Checking on Next Steps: 100,009
- Sample Submissions: 4,858

GROWTH OPPORTUNITY
1.7% who take quiz and meet national (NCCN) criteria convert to complete myRisk tests.
“Katie”
34 years old, worried but never had cancer

“I have a lot of cancer in my family, I wonder if I’m at risk too”

Searches to see how to get tested

“Visits Myriad.com to take Hereditary Cancer Quiz”

Qualifies for test

Now What?
Virtual appointment with a physician
Learn more through educational resources

No action and drops off

Current Conversion rate: 1.7%
myRisk® Patient journey – Future State

“Katie”

34 years old, worried
but never had cancer

Sees targeted ads on social media
Visits Myriad.com to check risk per family history
Qualifies for test & receives real-time cost estimate
Personal follow-up call from Myriad within 24 hours

Scenario 1
Has a physician

1.0 Katie gets test kit delivered. Takes to physician
1.1 Katie wants information. Talks to Myriad rep. Katie or rep contacts physician.

Scenario 2
2 - No Physician

2.0 Myriad rep helps Katie find a physician
2.2 Katie gets a call from Genetic Counselor, Physician, or Nurse. Kit order facilitated.
Announced Divestitures – Increasing Core Focus

- Simplifies the business, improves execution
- Slightly accretive without capital deployment
- Substantial cash proceeds for reinvestment
- Significant inbound interest; likely to close in 1H CY21
Key Drivers Impacting Operating Income in CY21

- $40M in cost savings
- $5M international restructuring
- COVID-19 Volume recovery
- New reimbursement, Revenue cycle opportunities
- $20M strategic reinvestment
- Post-COVID expense increases
Unlocking the power of genetics to improve and transform lives